Geron Corp (GERN)

2.87
0.01 0.52
NASDAQ : Health Care
Prev Close 2.88
Open 2.88
Day Low/High 2.84 / 2.91
52 Wk Low/High 2.30 / 5.30
Volume 228.56K
Avg Volume 1.39M
Exchange NASDAQ
Shares Outstanding 159.18M
Market Cap 445.69M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of December 15th Options Trading For Geron (GERN)

Investors in Geron Corp. saw new options become available this week, for the December 15th expiration.

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

Biotech Premarket Movers: Innoviva, Akebia, Geron

Biotech Premarket Movers: Innoviva, Akebia, Geron

Innoviva, Akebia Therapeutics and Geron were among the biotech stock movers in premarket trading on Tuesday.

Geron Corporation Reports Fourth Quarter And Annual 2016 Financial Results

Conference Call Scheduled for 4:30 p.m. ET Today, March 1

Interesting GERN Call Options For September 15th

Interesting GERN Call Options For September 15th

Investors in Geron Corp. saw new options become available this week, for the September 15th expiration.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Geron Corporation Reports Third Quarter 2016 Financial Results And Recent Events

Geron Corporation Reports Third Quarter 2016 Financial Results And Recent Events

Conference Call Scheduled for 4:30 p.m. EDT Today, November 3

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal

Geron (GERN) announced on Monday that it agreed to a licensing deal with Janssen Pharmaceuticals worth $80 million.

Geron Provides Update On Imetelstat Trials Being Conducted By Janssen

Geron Provides Update On Imetelstat Trials Being Conducted By Janssen

Conference Call Scheduled for 8:00 a.m. EDT Today, September 12

Geron Corporation Reports Second Quarter 2016 Financial Results And Recent Events

Geron Corporation Reports Second Quarter 2016 Financial Results And Recent Events

Conference Call Scheduled for 4:30 p.m. EDT Today, August 3

Geron (GERN) Is Today's Strong On High Volume Stock

Geron (GERN) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate

July 15th Options Now Available For Geron (GERN)

July 15th Options Now Available For Geron (GERN)

Investors in Geron Corp. saw new options become available today, for the July 15th expiration.

Geron Corporation Reports First Quarter 2016 Financial Results And Recent Events

Geron Corporation Reports First Quarter 2016 Financial Results And Recent Events

Conference Call Scheduled for 4:30 p.m. EDT Today, May 5